Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BofA Securities

Carnival Extends Time For Equity Offering

Carnival Corp (NYSE:CCL) has extended its share purchase program until April 30, 2022, under the same terms, from the previous date of January 31, 2022. The company had offered to sell shares of its common stock through its agent BofA Securities, having an aggregate offering price of up to $500 million. As announced…

Why This Crescent Capital BDC Analyst Is Bullish

Why This Crescent Capital BDC Analyst Is Bullish

Crescent Capital BDC Inc (NASDAQ: CCAP) has been gaining share in the middle market, where demand for capital “remains robust,” according to BofA Securities.

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BofA Expecting Earnings Beat From GM, But Misses From Ford And Tesla: What Investors Need To Know

Although expectations in the automotive industry have been “set reasonably low” heading into the quarter, investors are likely to focus on outlooks for 2022 and beyond, according to BofA Securities.

Why This BofA Securities Analyst Is Cutting Airline Price Targets

The underlying fundamentals in the airline sector remain challenging. Against this backdrop, investors should focus on quality names such as Delta Air Lines, Inc.

5 Reasons Blue Owl Capital Should Generate Strong Earnings Growth

Although Blue Owl Capital Inc.’s (NYSE: OWL) stock has been underperforming, the company enjoys a high-growth, high-margin and capital-light business, according to BofA Securities.

Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals

Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities.

inkl

Read news from The Economist, FT, and more,
with one subscription

BofA Downgrades CureVac On Limited 2022 Prospects

BofA Downgrades CureVac On Limited 2022 Prospects

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.

Why BofA Upgrades CH Robinson Worldwide

Why BofA Upgrades CH Robinson Worldwide

Brokerage carriers such as CH Robinson Worldwide Inc (NASDAQ: CHRW) are poised to benefit from continued strength in contract rates in the first half of 2022 and the subsequent “roll over as fluidity improves in the supply chain,” according to BofA Securities.

Why This Analyst Is Worried About Opendoor's iBuying Model In 2022

Why This Analyst Is Worried About Opendoor's iBuying Model In 2022

While Opendoor Technologies Inc (NASDAQ: OPEN) had strong revenues and increasing potential to gain market share, the iBuying model is “inherently risky, low margin, and capital intensive,” according to BofA Securities.

Why This Tesla Analyst Is Projecting Sharp Drop In Market Share, Benefits For Legacy Automakers

Why This Tesla Analyst Is Projecting Sharp Drop In Market Share, Benefits For Legacy Automakers

Tesla, Inc. (NASDAQ: TSLA), which has a commanding position in the U.S. electric vehicle market, could see an erosion in market share in the medium term, according to a BofA Securities analyst.

Are Netflix Shares Headed To $750?

Are Netflix Shares Headed To $750?

Having fallen about 15% to kick off the year, Netflix Inc (NASDAQ: NFLX) is on pace to record its worst monthly performance since October 2018. BofA Securities analyst Nat Schindler said he remains bullish on the streaming giant.

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Delta Air Lines

BofA Securities

Delta Air Lines, Inc.

Krystal Biotech

Ginkgo Bioworks Holdings Inc

Opendoor Technologies Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

277,692 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play